Abstract
Aim: The survival rates of cancer patients have greatly improved owing to the advances in oncology. The preservation of fertility in cancer patients is an important task. To determine the reality of cryopreservation of embryos, oocytes and ovarian tissue in cancer patients, large-scale survey analysis was performed in Japan. Methods: We sent 613 Japan Society of Obstetrics and Gynecology-certified assisted reproductive technology institutions a questionnaire about their experience of performing cryopreservation for cancer patients between January 2011 and December 2015. Subsequently, the institutions that conducted cryopreservation for cancer patients were sent a second questionnaire. Results: We received replies from 481 (78.5%) institutions. Among them, 126 (26.2%) conducted cryopreservation for cancer patients. These 126 institutions were sent a second questionnaire. Of these, 108 (85.7%) institutions responded. At the 108 institutions, 1085 embryo or oocyte cryopreservation procedures and 122 ovarian tissue cryopreservation procedures were conducted for cancer patients. Cryopreservation was mainly performed for breast cancer patients (~70%), followed by patients with hematological malignancy. A total of 361 and 19 embryo transfer cycles were performed for patients whose embryos and oocytes were cryopreserved, respectively, and 42 and seven institutions reported pregnancy outcomes after embryo transfer in patients that underwent embryo and oocyte cryopreservation, respectively. However, pregnancy was not observed in the seven cases that underwent ovarian tissue transfer. Conclusion: Indications, age limits and ovarian stimulation protocols for cryopreservation widely varied between the institutions. A national registration system for oncofertility must be established to evaluate the safety and efficacy of the current system.
| Original language | English |
|---|---|
| Pages (from-to) | 2021-2028 |
| Number of pages | 8 |
| Journal | Journal of Obstetrics and Gynaecology Research |
| Volume | 45 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 2019 Oct 1 |
Fingerprint
Keywords
- assisted reproductive technology
- breast cancer
- controlled ovarian stimulation
- cryopreservation
- oncofertility
ASJC Scopus subject areas
- Obstetrics and Gynaecology
Cite this
A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients. / Sanada, Yuko; Harada, Miyuki; Kunitomi, Chisato; Kanatani, Mayuko; Izumi, Gentaro; Hirata, Tetsuya; Fujii, Tomoyuki; Suzuki, Nao; Morishige, Ken ichirou; Aoki, Daisuke; Irahara, Minoru; Tsugawa, Koichiro; Tanimoto, Mitsune; Nishiyama, Hiroyuki; Hosoi, Hajime; Sugiyama, Kazuhiko; Kawai, Akira; Osuga, Yutaka.
In: Journal of Obstetrics and Gynaecology Research, Vol. 45, No. 10, 01.10.2019, p. 2021-2028.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients
AU - Sanada, Yuko
AU - Harada, Miyuki
AU - Kunitomi, Chisato
AU - Kanatani, Mayuko
AU - Izumi, Gentaro
AU - Hirata, Tetsuya
AU - Fujii, Tomoyuki
AU - Suzuki, Nao
AU - Morishige, Ken ichirou
AU - Aoki, Daisuke
AU - Irahara, Minoru
AU - Tsugawa, Koichiro
AU - Tanimoto, Mitsune
AU - Nishiyama, Hiroyuki
AU - Hosoi, Hajime
AU - Sugiyama, Kazuhiko
AU - Kawai, Akira
AU - Osuga, Yutaka
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Aim: The survival rates of cancer patients have greatly improved owing to the advances in oncology. The preservation of fertility in cancer patients is an important task. To determine the reality of cryopreservation of embryos, oocytes and ovarian tissue in cancer patients, large-scale survey analysis was performed in Japan. Methods: We sent 613 Japan Society of Obstetrics and Gynecology-certified assisted reproductive technology institutions a questionnaire about their experience of performing cryopreservation for cancer patients between January 2011 and December 2015. Subsequently, the institutions that conducted cryopreservation for cancer patients were sent a second questionnaire. Results: We received replies from 481 (78.5%) institutions. Among them, 126 (26.2%) conducted cryopreservation for cancer patients. These 126 institutions were sent a second questionnaire. Of these, 108 (85.7%) institutions responded. At the 108 institutions, 1085 embryo or oocyte cryopreservation procedures and 122 ovarian tissue cryopreservation procedures were conducted for cancer patients. Cryopreservation was mainly performed for breast cancer patients (~70%), followed by patients with hematological malignancy. A total of 361 and 19 embryo transfer cycles were performed for patients whose embryos and oocytes were cryopreserved, respectively, and 42 and seven institutions reported pregnancy outcomes after embryo transfer in patients that underwent embryo and oocyte cryopreservation, respectively. However, pregnancy was not observed in the seven cases that underwent ovarian tissue transfer. Conclusion: Indications, age limits and ovarian stimulation protocols for cryopreservation widely varied between the institutions. A national registration system for oncofertility must be established to evaluate the safety and efficacy of the current system.
AB - Aim: The survival rates of cancer patients have greatly improved owing to the advances in oncology. The preservation of fertility in cancer patients is an important task. To determine the reality of cryopreservation of embryos, oocytes and ovarian tissue in cancer patients, large-scale survey analysis was performed in Japan. Methods: We sent 613 Japan Society of Obstetrics and Gynecology-certified assisted reproductive technology institutions a questionnaire about their experience of performing cryopreservation for cancer patients between January 2011 and December 2015. Subsequently, the institutions that conducted cryopreservation for cancer patients were sent a second questionnaire. Results: We received replies from 481 (78.5%) institutions. Among them, 126 (26.2%) conducted cryopreservation for cancer patients. These 126 institutions were sent a second questionnaire. Of these, 108 (85.7%) institutions responded. At the 108 institutions, 1085 embryo or oocyte cryopreservation procedures and 122 ovarian tissue cryopreservation procedures were conducted for cancer patients. Cryopreservation was mainly performed for breast cancer patients (~70%), followed by patients with hematological malignancy. A total of 361 and 19 embryo transfer cycles were performed for patients whose embryos and oocytes were cryopreserved, respectively, and 42 and seven institutions reported pregnancy outcomes after embryo transfer in patients that underwent embryo and oocyte cryopreservation, respectively. However, pregnancy was not observed in the seven cases that underwent ovarian tissue transfer. Conclusion: Indications, age limits and ovarian stimulation protocols for cryopreservation widely varied between the institutions. A national registration system for oncofertility must be established to evaluate the safety and efficacy of the current system.
KW - assisted reproductive technology
KW - breast cancer
KW - controlled ovarian stimulation
KW - cryopreservation
KW - oncofertility
UR - http://www.scopus.com/inward/record.url?scp=85072848513&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072848513&partnerID=8YFLogxK
U2 - 10.1111/jog.14073
DO - 10.1111/jog.14073
M3 - Article
C2 - 31364239
AN - SCOPUS:85072848513
VL - 45
SP - 2021
EP - 2028
JO - Asia-Oceania Journal of Obstetrics and Gynaecology
JF - Asia-Oceania Journal of Obstetrics and Gynaecology
SN - 1341-8076
IS - 10
ER -